Compare NetApp Inc. (NTAP) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? NetApp Inc. trades at $218.8 (market cap $46.95B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: NetApp Inc. is far larger — about 9.6× Travere Therapeutics Inc. Common Stock's market cap, and NetApp Inc. pays a 0.87% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetApp Inc. for 57 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| NTAP | TVTX | |
|---|---|---|
Market Cap | $46.95B | $4.88B |
Volume | 2,358,705 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $239.23 | $67.52 |
52-Week Low | $94.11 | $26.79 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | $45.90B | $5.01B |
Dividend Yield | 0.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetApp (NTAP) trades at $222.2, down 7.12% over the past day, yet maintains a strong fundamental profile with robust profitability margins and consistent earnings beats. The stock exhibits a bullish technical signal, supported by moving averages, though oscillators indicate potential overbought conditions. Recent strategic announcements at INSIGHT 2026, including AI infrastructure partnerships and new product launches, highlight the company's focus on capitalizing on data and AI-driven demand.
The outlook for NTAP is positive, driven by solid earnings growth, strategic AI initiatives, and favorable analyst sentiment, but risks include high valuation multiples, competitive pressures in the storage sector, and macroeconomic sensitivity. The consensus price target of $219.30 suggests limited near-term upside from current levels, warranting caution amid recent volatility.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
